People living with motor neuron disease (MND) will have more opportunities to participate in groundbreaking research, thanks ...

The phase II DAZALS study evaluating Corcept's dazucorilant in patients with amyotrophic lateral sclerosis fails to meet the primary goal.

Corcept Therapeutics’ selective cortisol modulator failed to slow the progress of amyotrophic lateral sclerosis (ALS) in a ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe e ...

Community members are launching into action to help fund medical bills for Carpinterian Lisa Burch, 61, who has Amyotrophic ...

Corcept's drug dazucorilant failed to meet its primary endpoint during a Phase 2 trial to slow the decline in motor and functional skills in patients with Amyotrophic Lateral Sclerosis, or ALS.

Corcept Therapeutics said on Wednesday its experimental drug failed to meet the main goal of a mid-stage trial in patients ...

Scientists are uncovering new insights into the mechanisms driving neurodegenerative disorders, including amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). These fatal diseases ...

Therapeutics announced it has concluded a Type C meeting with the FDA for PrimeC in the treatment of amyotrophic lateral ...

The company’s lead asset, CNM-Au8, is showing potential efficacy in treating amyotrophic lateral sclerosis (ALS), with plans for a New Drug Application (NDA) filing in mid-2025. This move is backed by ...

A new system developed by Icahn Mount Sinai researchers enables the safe delivery of therapeutic biomolecules to the brain by ...

Some things are simply meant to be. That was the case for Nicholas Potter when took over his late father's Santa Fe bookstore in 1975. "From day one, I realized it was exactly what I should be doing ...